alnylam pharmaceuticals - ALNY
ALNY
Close Chg Chg %
248.79 -1.99 -0.80%
Closed Market
246.80
-1.99 (0.80%)
Volume: 687.21K
Last Updated:
Nov 21, 2024, 4:00 PM EDT
Company Overview: alnylam pharmaceuticals - ALNY
ALNY Key Data
| Open $249.41 | Day Range 245.32 - 250.68 |
| 52 Week Range 141.98 - 304.39 | Market Cap $32.09B |
| Shares Outstanding 128.98M | Public Float 127.95M |
| Beta 0.39 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$2.62 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 923.51K |
ALNY Performance
| 1 Week | 4.77% | ||
| 1 Month | -13.36% | ||
| 3 Months | -9.48% | ||
| 1 Year | 51.49% | ||
| 5 Years | 130.85% |
ALNY Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
33
Full Ratings ➔
About alnylam pharmaceuticals - ALNY
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
ALNY At a Glance
Alnylam Pharmaceuticals, Inc.
675 West Kendall Street
Cambridge, Massachusetts 02142
| Phone | 1-617-551-8200 | Revenue | 1.83B | |
| Industry | Pharmaceuticals: Major | Net Income | -440,242,000.00 | |
| Sector | Health Technology | 2023 Sales Growth | 76.235% | |
| Fiscal Year-end | 12 / 2024 | Employees | 2,100 | |
| View SEC Filings |
ALNY Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 13.077 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | 229.543 |
| Enterprise Value to EBITDA | -105.871 |
| Enterprise Value to Sales | 13.21 |
| Total Debt to Enterprise Value | 0.111 |
ALNY Efficiency
| Revenue/Employee | 870,615.238 |
| Income Per Employee | -209,639.048 |
| Receivables Turnover | 5.578 |
| Total Asset Turnover | 0.496 |
ALNY Liquidity
| Current Ratio | 3.082 |
| Quick Ratio | 2.99 |
| Cash Ratio | 2.521 |
ALNY Profitability
| Gross Margin | 83.022 |
| Operating Margin | -15.434 |
| Pretax Margin | -23.712 |
| Net Margin | -24.079 |
| Return on Assets | -11.937 |
| Return on Equity | N/A |
| Return on Total Capital | -17.882 |
| Return on Invested Capital | -18.585 |
ALNY Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 108.962 |
| Total Debt to Total Assets | 70.045 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 105.042 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Alnylam Pharmaceuticals - ALNY
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 492.85M | 844.29M | 1.04B | 1.83B | |
Sales Growth
| +124.28% | +71.31% | +22.88% | +76.23% | |
Cost of Goods Sold (COGS) incl D&A
| 78.05M | 140.14M | 168.82M | 310.41M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 34.77M | 47.57M | 44.47M | 54.05M | |
Depreciation
| - | 36.80M | 39.10M | 51.60M | |
Amortization of Intangibles
| - | 10.77M | 5.37M | 2.45M | |
COGS Growth
| +211.44% | +79.55% | +20.46% | +83.87% | |
Gross Income
| 414.80M | 704.14M | 868.60M | 1.52B | |
Gross Income Growth
| +113.06% | +69.75% | +23.36% | +74.75% | |
Gross Profit Margin
| +84.16% | +83.40% | +83.73% | +83.02% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 1.24B | 1.41B | 1.65B | 1.80B | |
Research & Development
| 654.82M | 792.16M | 883.01M | 1.00B | |
Other SG&A
| 588.42M | 620.64M | 770.66M | 795.65M | |
SGA Growth
| +9.62% | +13.64% | +17.05% | +8.85% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 17.18M | 38.43M | 171.25M | 91.00M | |
EBIT after Unusual Expense
| (845.62M) | (747.09M) | (956.32M) | (373.17M) | |
Non Operating Income/Expense
| 74.52M | 37.96M | (14.71M) | 60.88M | |
Non-Operating Interest Income
| 11.81M | 1.58M | 24.81M | 95.56M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 84.50M | 143.02M | 155.97M | 121.22M | |
Interest Expense Growth
| - | +69.26% | +9.05% | -22.28% | |
Gross Interest Expense
| 84.50M | 143.02M | 155.97M | 121.22M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (855.60M) | (852.14M) | (1.13B) | (433.52M) | |
Pretax Income Growth
| +3.35% | +0.40% | -32.25% | +61.53% | |
Pretax Margin
| -173.60% | -100.93% | -108.63% | -23.71% | |
Income Tax
| 2.68M | 680.00K | 4.16M | 6.72M | |
Income Tax - Current - Domestic
| - | 61.00K | 293.00K | 4.02M | |
Income Tax - Current - Foreign
| 5.84M | 3.15M | 5.60M | 3.42M | |
Income Tax - Deferred - Domestic
| - | - | - | 393.00K | - |
Income Tax - Deferred - Foreign
| (3.61M) | (2.77M) | (1.43M) | (713.00K) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (858.28M) | (852.82M) | (1.13B) | (440.24M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (858.28M) | (852.82M) | (1.13B) | (440.24M) | |
Net Income Growth
| +3.14% | +0.64% | -32.64% | +61.08% | |
Net Margin Growth
| -174.15% | -101.01% | -109.04% | -24.08% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (858.28M) | (852.82M) | (1.13B) | (440.24M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (858.28M) | (852.82M) | (1.13B) | (440.24M) | |
EPS (Basic)
| -7.4642 | -7.1998 | -9.2955 | -3.5246 | |
EPS (Basic) Growth
| +7.96% | +3.54% | -29.11% | +62.08% | |
Basic Shares Outstanding
| 114.99M | 118.45M | 121.69M | 124.91M | |
EPS (Diluted)
| -7.4642 | -7.1998 | -9.2955 | -3.5246 | |
EPS (Diluted) Growth
| +7.96% | +3.54% | -29.11% | +62.08% | |
Diluted Shares Outstanding
| 114.99M | 118.45M | 121.69M | 124.91M | |
EBITDA
| (793.67M) | (661.09M) | (740.60M) | (228.12M) | |
EBITDA Growth
| +13.94% | +16.70% | -12.03% | +69.20% | |
EBITDA Margin
| -161.04% | -78.30% | -71.39% | -12.48% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 309.80 | |
| Number of Ratings | 33 | Current Quarters Estimate | -0.586 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | -1.973 | |
| Last Quarter’s Earnings | -0.87 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -3.52 | Next Fiscal Year Estimate | -1.083 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 24 | 10 | 25 | 26 |
| Mean Estimate | -0.59 | -0.69 | -1.97 | -1.08 |
| High Estimates | 0.70 | -0.28 | -0.67 | 2.70 |
| Low Estimate | -1.40 | -1.03 | -2.94 | -3.70 |
| Coefficient of Variance | -73.96 | -39.38 | -26.50 | -183.94 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 18 | 18 | 16 |
| OVERWEIGHT | 5 | 5 | 5 |
| HOLD | 8 | 9 | 9 |
| UNDERWEIGHT | 1 | 1 | 1 |
| SELL | 1 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Alnylam Pharmaceuticals - ALNY
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Alnylam Pharmaceuticals - ALNY
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Oct 4, 2024 | Robert W. Hesslein EVP, CLO and Secretary | 7,245 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Aug 23, 2024 | Yvonne L. Greenstreet Chief Executive Officer; Director | 88,441 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $85 per share | 7,517,485.00 |
| Aug 23, 2024 | Yvonne L. Greenstreet Chief Executive Officer; Director | 2,352 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 23, 2024 | Yvonne L. Greenstreet Chief Executive Officer; Director | 73,441 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $280 per share | 20,563,480.00 |
| Aug 9, 2024 | Dennis Arthur Ausiello Director | 20,386 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $105.26 per share | 2,145,830.36 |
| Aug 9, 2024 | Dennis Arthur Ausiello Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 9, 2024 | Dennis Arthur Ausiello Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 9, 2024 | Dennis Arthur Ausiello Director | 136 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $266.45 per share | 36,237.20 |
| Aug 9, 2024 | Dennis Arthur Ausiello Director | 398 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $264.95 per share | 105,450.10 |
| Aug 9, 2024 | Dennis Arthur Ausiello Director | 1,030 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $263.72 per share | 271,631.60 |
| Aug 9, 2024 | Dennis Arthur Ausiello Director | 4,438 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $262.79 per share | 1,166,262.02 |
| Aug 9, 2024 | Dennis Arthur Ausiello Director | 8,805 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $261.63 per share | 2,303,652.15 |
| Aug 9, 2024 | Dennis Arthur Ausiello Director | 15,017 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $260.4 per share | 3,910,426.80 |
| Aug 9, 2024 | Dennis Arthur Ausiello Director | 18,759 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $259.56 per share | 4,869,086.04 |
| Aug 9, 2024 | Dennis Arthur Ausiello Director | 11,386 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $131.21 per share | 1,493,957.06 |
| Jun 28, 2024 | Amy L. Schulman Director | 2,750 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 28, 2024 | Amy L. Schulman Director | 8,436 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $240 per share | 2,024,640.00 |
| Jun 28, 2024 | Amy L. Schulman Director | 16,936 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $131.21 per share | 2,222,172.56 |
| May 21, 2024 | Margaret A. Hamburg Director | 5,228 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 21, 2024 | Charles Elliott Sigal Director | 5,228 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
Alnylam Pharmaceuticals in the News
Calls to boycott McDonald's, other brands in wake of Russia's invasion of Ukraine
Major global brands, including McDonald's Corp, PepsiCo Inc. and the Estee Lauder Cos Inc. should consider pausing their operations in Russia, New York state's pension fund chief wrote in letters to several companies on Friday.